• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?

作者信息

Niscola Pasquale, Gianfelici Valentina, Giovannini Marco, Piccioni Daniela, Mazzone Carla, Fabritiis Paolo de

机构信息

Hematology Unit, Sant 'Eugenio Hospital of Rome, ASL Roma 2, Rome, Italy.

出版信息

Ann Hematol. 2024 May;103(5):1787-1788. doi: 10.1007/s00277-024-05700-4. Epub 2024 Mar 9.

DOI:10.1007/s00277-024-05700-4
PMID:38459155
Abstract
摘要

相似文献

1
Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?维奈克拉联合去甲基化药物治疗两名老年急性髓系白血病患者的长期疗效：是否到了采用治疗中断策略的时候？
Ann Hematol. 2024 May;103(5):1787-1788. doi: 10.1007/s00277-024-05700-4. Epub 2024 Mar 9.
2
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
3
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.维奈克拉联合地西他滨或阿扎胞苷简化方案治疗急性髓系白血病
Leuk Res. 2023 Nov;134:107370. doi: 10.1016/j.leukres.2023.107370. Epub 2023 Aug 16.
4
Toward an improved understanding of hypomethylating agent and venetoclax therapies.旨在更好地理解去甲基化药物和维奈托克疗法。
Am J Hematol. 2024 Feb;99(2):152-154. doi: 10.1002/ajh.27178. Epub 2023 Dec 15.
5
Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen.新诊断成人急性髓系白血病诱导治疗中联合低甲基化药物与标准 7+3 方案的临床状态比较。
Expert Rev Hematol. 2023 Jul-Dec;16(10):761-771. doi: 10.1080/17474086.2023.2256472. Epub 2023 Sep 8.
6
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.低甲基化药物联合维奈托克治疗急性髓系白血病：临床试验数据更新及实际应用注意事项。
Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13.
7
Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.维奈托克联合低甲基化药物治疗复发/难治性急性髓系白血病：来自单中心的病例系列。
J BUON. 2021 Sep-Oct;26(5):2026-2032.
8
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.一项在门诊环境中进行的 Venetoclax 联合阿扎胞苷或地西他滨治疗急性髓系白血病患者的 3b 期研究。
Hematol Oncol. 2024 May;42(3):e3274. doi: 10.1002/hon.3274.
9
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.地西他滨和西扎珠苷加维奈克拉的全口服方案：老年或身体状况不佳的急性髓系白血病患者的新进展。
Lancet Haematol. 2024 Apr;11(4):e245-e246. doi: 10.1016/S2352-3026(24)00060-7. Epub 2024 Mar 4.
10
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.传统细胞遗传学对接受维奈克拉和地西他滨治疗的急性髓系白血病的预后影响
Leuk Lymphoma. 2021 Dec;62(14):3501-3505. doi: 10.1080/10428194.2021.1973675. Epub 2021 Sep 3.

引用本文的文献

1
Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis.AML60+评分对接受去甲基化药物治疗的老年急性髓系白血病患者的预后影响：一项回顾性多中心分析
Cancers (Basel). 2025 Aug 14;17(16):2658. doi: 10.3390/cancers17162658.
2
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.老年急性髓系白血病：从新的生物学见解到靶向治疗。
Curr Oncol. 2024 Oct 24;31(11):6632-6658. doi: 10.3390/curroncol31110490.

本文引用的文献

1
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?NPM1 突变型急性髓系白血病稳定分子缓解期髓系肿瘤的发生：我们面对的是继发性疾病还是急性髓系白血病复发？
Blood Cancer J. 2023 Dec 21;13(1):194. doi: 10.1038/s41408-023-00959-8.
2
Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies.维奈托克联合低甲基化药物治疗新诊断的急性髓系白血病：来自真实世界研究生存数据的系统评价和荟萃分析
Cancers (Basel). 2023 Sep 18;15(18):4618. doi: 10.3390/cancers15184618.
3
Acute Myeloid Leukemia with NPM1 Mutation and Disseminated Leukemia Cutis: Achievement of Molecular Complete Remission by Venetoclax/Azacitidine Combination in a Very Old Patient.
伴 NPM1 突变和播散性皮肤白血病的急性髓系白血病：维奈托克/阿扎胞苷联合治疗高龄患者达到分子完全缓解。
Acta Haematol. 2023;146(5):408-412. doi: 10.1159/000531101. Epub 2023 May 17.
4
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.新诊断的急性髓系白血病中基于微小残留病灶指导的阿扎胞苷停药的高剂量维奈托克。
Haematologica. 2023 Oct 1;108(10):2616-2625. doi: 10.3324/haematol.2023.282681.
5
An NGS based MRD evaluation from acute myeloid leukemia patients.基于 NGS 的急性髓系白血病患者微小残留病灶评估。
Int J Lab Hematol. 2023 Jun;45(3):353-359. doi: 10.1111/ijlh.14034. Epub 2023 Feb 7.
6
Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax.一名老年急性髓系白血病患者在接受有限疗程的阿扎胞苷和维奈克拉治疗后实现持久缓解。
Leuk Res Rep. 2022 Aug 17;18:100345. doi: 10.1016/j.lrr.2022.100345. eCollection 2022.
7
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia.停止基于 venetoclax 的治疗后急性髓系白血病患者的无治疗缓解。
Blood Adv. 2022 Jul 12;6(13):3879-3883. doi: 10.1182/bloodadvances.2022007083.
8
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.维奈托克联合阿扎胞苷治疗初治急性髓系白血病的微小残留病反应与预后。
J Clin Oncol. 2022 Mar 10;40(8):855-865. doi: 10.1200/JCO.21.01546. Epub 2021 Dec 15.
9
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.